Swiss National Bank cut its stake in shares of Intrexon Corp (NASDAQ:XON) by 16.4% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 114,900 shares of the biotechnology company’s stock after selling 22,600 shares during the quarter. Swiss National Bank’s holdings in Intrexon were worth $879,000 as of its most recent filing with the SEC.
Several other hedge funds and other institutional investors also recently modified their holdings of the business. Aperio Group LLC purchased a new position in Intrexon during the second quarter worth about $94,000. Janney Montgomery Scott LLC boosted its holdings in shares of Intrexon by 39.7% in the 2nd quarter. Janney Montgomery Scott LLC now owns 41,615 shares of the biotechnology company’s stock worth $319,000 after purchasing an additional 11,825 shares in the last quarter. Nikko Asset Management Americas Inc. boosted its holdings in Intrexon by 133.9% during the 2nd quarter. Nikko Asset Management Americas Inc. now owns 2,704,014 shares of the biotechnology company’s stock valued at $20,713,000 after acquiring an additional 1,548,194 shares during the period. Sumitomo Mitsui Trust Holdings Inc. boosted its holdings in Intrexon by 138.9% during the 2nd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 2,704,014 shares of the biotechnology company’s stock valued at $20,713,000 after acquiring an additional 1,572,077 shares during the period. Finally, Steward Partners Investment Advisory LLC purchased a new stake in Intrexon during the 2nd quarter valued at about $58,000. 75.74% of the stock is owned by institutional investors.
In related news, insider Helen Sabzevari sold 8,484 shares of the firm’s stock in a transaction that occurred on Thursday, July 18th. The stock was sold at an average price of $7.47, for a total transaction of $63,375.48. Following the completion of the transaction, the insider now owns 70,825 shares of the company’s stock, valued at approximately $529,062.75. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Donald P. Lehr sold 4,822 shares of the firm’s stock in a transaction that occurred on Monday, July 1st. The shares were sold at an average price of $7.76, for a total value of $37,418.72. Following the transaction, the insider now directly owns 62,298 shares of the company’s stock, valued at approximately $483,432.48. The disclosure for this sale can be found here. Insiders sold a total of 22,672 shares of company stock valued at $173,474 in the last three months. Corporate insiders own 44.00% of the company’s stock.
XON traded down $0.18 during midday trading on Thursday, reaching $6.18. 8,283 shares of the company’s stock traded hands, compared to its average volume of 2,054,197. The firm has a fifty day moving average price of $6.67. The company has a market cap of $1.05 billion, a PE ratio of -4.49 and a beta of 2.36. The company has a quick ratio of 3.20, a current ratio of 3.55 and a debt-to-equity ratio of 0.90. Intrexon Corp has a 52 week low of $3.95 and a 52 week high of $19.94.
Intrexon (NASDAQ:XON) last released its quarterly earnings results on Thursday, August 8th. The biotechnology company reported ($0.25) EPS for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.05. The business had revenue of $35.99 million during the quarter, compared to analyst estimates of $29.62 million. Intrexon had a negative return on equity of 31.89% and a negative net margin of 368.47%. Intrexon’s quarterly revenue was down 20.6% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.51) EPS. As a group, equities analysts predict that Intrexon Corp will post -0.9 earnings per share for the current fiscal year.
Several equities research analysts recently weighed in on XON shares. ValuEngine upgraded Intrexon from a “sell” rating to a “hold” rating in a report on Thursday, August 1st. Northland Securities restated a “hold” rating and set a $10.00 target price on shares of Intrexon in a report on Monday, August 12th. Bank of America dropped their target price on Intrexon from $7.00 to $6.00 and set an “underperform” rating for the company in a report on Friday, August 9th. Finally, BidaskClub cut Intrexon from a “buy” rating to a “hold” rating in a report on Tuesday, August 6th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and two have assigned a buy rating to the stock. The company presently has an average rating of “Hold” and an average price target of $17.00.
Intrexon Corporation operates in the synthetic biology field in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components. Its technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing; and ActoBiotics and AdenoVerse technology platforms.
Recommended Story: Buy-Side Analysts
Want to see what other hedge funds are holding XON? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intrexon Corp (NASDAQ:XON).
Receive News & Ratings for Intrexon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon and related companies with MarketBeat.com's FREE daily email newsletter.